High Expression of a Cancer Stemness-Related Gene, Chromobox 8 (CBX8), in Normal Tissue Adjacent to the Tumor (NAT) Is Associated with Poor Prognosis of Colorectal Cancer Patients.
CBX8
colorectal cancer
normal tissue adjacent to the tumor (NAT)
prognostic biomarker
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
06 06 2022
06 06 2022
Historique:
received:
21
03
2022
revised:
27
05
2022
accepted:
02
06
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
14
6
2022
Statut:
epublish
Résumé
Several studies have demonstrated that the molecular profile of normal tissue adjacent to the tumor (NAT) is prognostic for recurrence in patients with different cancers. This study investigated the clinical significance of CBX8 gene expression, a cancer stemness-related gene, in tumor and NAT tissue of colorectal cancer (CRC) patients. The gene level of CBX8 in paired CRC and NAT specimens from 95 patients was determined by quantitative PCR. CBX8 protein level in CRC and NAT specimens from 66 patients was determined by immunohistochemistry. CBX8 gene and protein levels were correlated with the patients' clinicopathological parameters and circulatory immune cell profiles. The association between NAT High NAT
Sections du résumé
BACKGROUND
Several studies have demonstrated that the molecular profile of normal tissue adjacent to the tumor (NAT) is prognostic for recurrence in patients with different cancers. This study investigated the clinical significance of CBX8 gene expression, a cancer stemness-related gene, in tumor and NAT tissue of colorectal cancer (CRC) patients.
METHODS
The gene level of CBX8 in paired CRC and NAT specimens from 95 patients was determined by quantitative PCR. CBX8 protein level in CRC and NAT specimens from 66 patients was determined by immunohistochemistry. CBX8 gene and protein levels were correlated with the patients' clinicopathological parameters and circulatory immune cell profiles. The association between
RESULTS
NAT
CONCLUSIONS
High NAT
Identifiants
pubmed: 35681547
pii: cells11111852
doi: 10.3390/cells11111852
pmc: PMC9180723
pii:
doi:
Substances chimiques
CBX8 protein, human
0
Uronic Acids
0
N-acetyltalosaminuronic acid
90319-06-5
Polycomb Repressive Complex 1
EC 2.3.2.27
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Mol Ther Oncolytics. 2020 Oct 04;19:188-196
pubmed: 33251331
Cell Chem Biol. 2022 Apr 21;29(4):555-571.e11
pubmed: 34715055
JAMA Oncol. 2018 Mar 01;4(3):309-315
pubmed: 29270608
Int J Mol Sci. 2019 May 11;20(9):
pubmed: 31083525
Cell Death Dis. 2020 Jan 6;11(1):10
pubmed: 31907353
Int J Colorectal Dis. 2011 Sep;26(9):1135-41
pubmed: 21538056
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Cancers (Basel). 2021 Jul 17;13(14):
pubmed: 34298800
Mol Cancer. 2015 Jun 30;14:125
pubmed: 26123544
Mol Carcinog. 2016 May;55(5):793-807
pubmed: 25917796
BMC Cancer. 2019 Jan 7;19(1):15
pubmed: 30612568
Br J Cancer. 2021 Mar;124(5):933-941
pubmed: 33257844
Int J Surg. 2015 Apr;16(Pt A):123-128
pubmed: 25771102
Nat Rev Cancer. 2008 Dec;8(12):976-90
pubmed: 19029958
Clin Cancer Res. 2016 Jul 15;22(14):3651-62
pubmed: 26957561
Med Sci Monit. 2018 Nov 01;24:7820-7827
pubmed: 30383736
Cell Death Dis. 2016 Mar 31;7:e2169
pubmed: 27031966
Mod Pathol. 2017 Oct;30(10):1387-1401
pubmed: 28731048
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Oncotarget. 2017 Apr 26;8(38):64373-64384
pubmed: 28969077
Bone. 2021 Feb;143:115659
pubmed: 32979540
Br J Cancer. 2004 Apr 19;90(8):1612-9
pubmed: 15083194
Mol Cancer Ther. 2018 Aug;17(8):1761-1772
pubmed: 29866746
Cancer Med. 2021 May;10(9):3139-3152
pubmed: 33818013
BMC Cancer. 2011 Oct 11;11:437
pubmed: 21989116
Mol Carcinog. 2021 Dec;60(12):813-825
pubmed: 34499772
Nature. 2014 Mar 20;507(7492):315-22
pubmed: 24476821
Mol Cancer. 2018 Jan 31;17(1):17
pubmed: 29386021
Cancer Med. 2021 Oct;10(19):6705-6713
pubmed: 34405573
Oncotarget. 2014 Nov 15;5(21):10778-90
pubmed: 25360999
Cell Biochem Biophys. 2015 Apr;71(3):1503-7
pubmed: 25398592
Cancers (Basel). 2020 Mar 10;12(3):
pubmed: 32164324
Ann Surg. 2018 Jun;267(6):1119-1125
pubmed: 28394869
Lancet. 2015 Mar 14;385(9972):977-1010
pubmed: 25467588
Integr Cancer Ther. 2021 Jan-Dec;20:15347354211058168
pubmed: 34802261
Cancer. 1953 Sep;6(5):963-8
pubmed: 13094644
Front Oncol. 2020 Sep 04;10:582667
pubmed: 33014884
PLoS One. 2015 Mar 27;10(3):e0123396
pubmed: 25815725
Cell Rep. 2016 Jul 12;16(2):472-486
pubmed: 27346354
Nat Commun. 2017 Oct 20;8(1):1077
pubmed: 29057876
Radiother Oncol. 2021 Jan;154:76-86
pubmed: 32941957
Front Oncol. 2021 Sep 23;11:632571
pubmed: 34631510
Cell Syst. 2018 Mar 28;6(3):282-300.e2
pubmed: 29596783
Mol Cancer Ther. 2018 Oct;17(10):2164-2175
pubmed: 30082472
Pharmacogenet Genomics. 2006 Aug;16(8):555-63
pubmed: 16847424
Nat Commun. 2021 Nov 18;12(1):6711
pubmed: 34795238
ACS Chem Biol. 2020 Jan 17;15(1):112-131
pubmed: 31755685
Gene. 2019 Jan 5;680:59-64
pubmed: 30243936
ChemMedChem. 2021 Oct 6;16(19):3027-3034
pubmed: 34174168
Front Oncol. 2020 May 20;10:671
pubmed: 32509572
Cell Death Dis. 2019 Jan 18;10(2):52
pubmed: 30718464
Clin Cancer Res. 2011 Jan 15;17(2):236-46
pubmed: 21059815
Mol Cancer. 2019 Dec 18;18(1):185
pubmed: 31849331